Drug Profile
Research programme: myelosuppression therapy - HiberCell
Alternative Names: Imprime WGPLatest Information Update: 15 Jan 2021
Price :
$50
*
At a glance
- Originator Biothera
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Myelosuppression
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Myelosuppression in USA (PO)
- 18 Sep 2006 Biothera has been awarded a SBIR grant for the treatment of acute radiation exposure with Imprime WGP™
- 25 Oct 2005 Preclinical trials in Myelosuppression in USA (PO)